Mersana Therapeutics
Cambridge
About Mersana Therapeutics
Mersana Therapeutics develops novel antibody-drug conjugates (ADCs) designed to treat cancer. The company’s platforms, Dolasynthen (cytotoxic payloads) and Immunosynthen (immunostimulatory payloads), enable the creation of tailored ADCs for specific cancer targets. Its pipeline features wholly owned and partnered candidates, including Emi-Le (emiltatug ledadotin; XMT-1660) targeting the protein B7-H4, and XMT-2056, which targets a novel epitope of the HER2 receptor. Mersana supports collaborations with other biopharmaceutical organizations to extend its ADC technology into additional indications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $655.6M
- Funding stage: M&A
- Last round: Post-IPO Debt (Jan 2021)
- Ticker: nasdaq:MRSN
- Website: mersana.com
- Phone: 617-498-0020
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/mersana-therapeutics-67880 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.